AAAAAA

   
Results: 1-14 |
Results: 14
BACKUP BONE-MARROW IS FREQUENTLY INEFFECTIVE IN PATIENTS WITH POOR PERIPHERAL-BLOOD STEM-CELL MOBILIZATION
Authors: WATTS MJ SULLIVAN AM LEVERETT D PENIKET AJ PERRY AR WILLIAMS CD DEVEREUX S GOLDSTONE AH LINCH DC
Citation: Mj. Watts et al., BACKUP BONE-MARROW IS FREQUENTLY INEFFECTIVE IN PATIENTS WITH POOR PERIPHERAL-BLOOD STEM-CELL MOBILIZATION, Journal of clinical oncology, 16(4), 1998, pp. 1554-1560
A CASE OF EBV-ASSOCIATED LYMPHOPROLIFERATIVE DISEASE FOLLOWING HIGH-DOSE THERAPY AND CD34-PURIFIED AUTOLOGOUS PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION
Authors: PENIKET AJ PERRY AR WILLIAMS CD MACMILLAN A WATTS MJ ISAACSON PG GOLDSTONE AH LINCH DC
Citation: Aj. Peniket et al., A CASE OF EBV-ASSOCIATED LYMPHOPROLIFERATIVE DISEASE FOLLOWING HIGH-DOSE THERAPY AND CD34-PURIFIED AUTOLOGOUS PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION, Bone marrow transplantation, 22(3), 1998, pp. 307-309
PROGENITOR-CELL YIELDS ARE FREQUENTLY POOR IN PATIENTS WITH HISTOLOGICALLY INDOLENT LYMPHOMAS ESPECIALLY WHEN MOBILIZED WITHIN 6 MONTHS OF PREVIOUS CHEMOTHERAPY
Authors: PERRY AR WATTS MJ PENIKET AJ GOLDSTONE AH LINCH DC
Citation: Ar. Perry et al., PROGENITOR-CELL YIELDS ARE FREQUENTLY POOR IN PATIENTS WITH HISTOLOGICALLY INDOLENT LYMPHOMAS ESPECIALLY WHEN MOBILIZED WITHIN 6 MONTHS OF PREVIOUS CHEMOTHERAPY, Bone marrow transplantation, 21(12), 1998, pp. 1201-1205
A SUCCESSFUL RE-INDUCTION IMMUNOTHERAPY REGIMEN FOR ACUTE-LEUKEMIA RELAPSING AFTER SIBLING ALLOGRAFT/
Authors: PERRY AR PENIKET AJ WATTS MJ INGS SJ GOLDSTONE AH MACKINNON S
Citation: Ar. Perry et al., A SUCCESSFUL RE-INDUCTION IMMUNOTHERAPY REGIMEN FOR ACUTE-LEUKEMIA RELAPSING AFTER SIBLING ALLOGRAFT/, Bone marrow transplantation, 21, 1998, pp. 246-246
TREATMENT WITH CAMPATH 1G LEADS TO EMERGENCE OF AN OCCULT PNH CLONE
Authors: MARKS AJ PERRY AR KOTTARIDIS PD PENIKET AJ HALE G WALDMANN H PATTERSON K RICHARDS S MACKINNON S
Citation: Aj. Marks et al., TREATMENT WITH CAMPATH 1G LEADS TO EMERGENCE OF AN OCCULT PNH CLONE, Bone marrow transplantation, 21, 1998, pp. 344-344
EVALUATION OF CLINICAL-SCALE CD34(- EXPERIENCE OF 71 IMMUNOAFFINITY COLUMN PROCEDURES() CELL PURIFICATION )
Authors: WATTS MJ SULLIVAN AM INGS SJ LEVERETT D PENIKET AJ PERRY AR WILLIAMS CD DEVEREUX S GOLDSTONE AH LINCH DC
Citation: Mj. Watts et al., EVALUATION OF CLINICAL-SCALE CD34(- EXPERIENCE OF 71 IMMUNOAFFINITY COLUMN PROCEDURES() CELL PURIFICATION ), Bone marrow transplantation, 20(2), 1997, pp. 157-162
THE LENGTH OF THE FIRST COMPLETE REMISSION (1-6 MONTHS, 7-12 MONTHS GREATER-THAN-12 MONTHS) DOES NOT PREDICT OUTCOME FOLLOWING BEAM AND AUTOTRANSPLANTATION FOR HODGKINS-DISEASE IN FIRST RELAPSE
Authors: KOTTARIDIS PD PENIKET AJ PERRY AR HARRISON CN DEELVIRA MCR MACMILLAN A DEVEREUX S LINCH DC GOLDSTONE AH
Citation: Pd. Kottaridis et al., THE LENGTH OF THE FIRST COMPLETE REMISSION (1-6 MONTHS, 7-12 MONTHS GREATER-THAN-12 MONTHS) DOES NOT PREDICT OUTCOME FOLLOWING BEAM AND AUTOTRANSPLANTATION FOR HODGKINS-DISEASE IN FIRST RELAPSE, Blood, 90(10), 1997, pp. 496-496
OUTCOME OF BEAM AUTOTRANSPLANTATION IN PATIENTS WITH HODGKINS-DISEASEPROGRESSING ON FIRST LINE THERAPY IS THE SAME AS IN PATIENTS TRANSPLANTED IN FIRST PARTIAL REMISSION
Authors: PENIKET AJ KOTTARIDIS PD PERRY AR DEELVIRA MCR DEVEREUX S MACMILLAN A GOLDSTONE AH LINCH DC
Citation: Aj. Peniket et al., OUTCOME OF BEAM AUTOTRANSPLANTATION IN PATIENTS WITH HODGKINS-DISEASEPROGRESSING ON FIRST LINE THERAPY IS THE SAME AS IN PATIENTS TRANSPLANTED IN FIRST PARTIAL REMISSION, Blood, 90(10), 1997, pp. 497-497
BACKUP BONE-MARROW IS FREQUENTLY INEFFECTIVE IN PATIENTS WITH POOR PERIPHERAL-BLOOD PROGENITOR-CELL MOBILIZATION
Authors: WATTS MJ SULLIVAN AM LEVERETT D PENIKET AJ WILLIAMS CD DEVEREUX S GOLDSTONE AH LINCH DC
Citation: Mj. Watts et al., BACKUP BONE-MARROW IS FREQUENTLY INEFFECTIVE IN PATIENTS WITH POOR PERIPHERAL-BLOOD PROGENITOR-CELL MOBILIZATION, Blood, 90(10), 1997, pp. 938-938
ALLOGENIC TRANSPLANTATION FOR LYMPHOMA PRODUCES A LOWER RELAPSE RATE THAN AUTOLOGOUS TRANSPLANTATION BUT SURVIVAL IS WORSE BECAUSE OF HIGHER TREATMENT RELATED MORTALITY - A REPORT OF 764 CASES FROM THE EBMT LYMPHOMA REGISTRY
Authors: PENIKET AJ DEELVIRA MCR TAGHIPOUR G DEWITTE T TAZELAAR PJ CARELLA A VERNANT JP SCHAEFER UW CLEEVEN M BOOGAERTS MA GLUCKMAN E GOLDSTONE AH
Citation: Aj. Peniket et al., ALLOGENIC TRANSPLANTATION FOR LYMPHOMA PRODUCES A LOWER RELAPSE RATE THAN AUTOLOGOUS TRANSPLANTATION BUT SURVIVAL IS WORSE BECAUSE OF HIGHER TREATMENT RELATED MORTALITY - A REPORT OF 764 CASES FROM THE EBMT LYMPHOMA REGISTRY, Blood, 90(10), 1997, pp. 1121-1121
WHICH PBPC PATIENTS MAY BENEFIT FROM ACCELERATED PLATELET RECOVERY - FACTORS AFFECTING HOSPITAL DISCHARGE IN 152 CONSECUTIVE PATIENTS, THE RELEVANCE OF CD34 DOSE AND THE POTENTIAL IMPLICATIONS OF MEGAKARYOCYTEGROWTH-FACTOR
Authors: PENIKET AJ PERRY AR LEVERETT D WATTS M SULLIVAN A LINCH DC GOLDSTONE AH
Citation: Aj. Peniket et al., WHICH PBPC PATIENTS MAY BENEFIT FROM ACCELERATED PLATELET RECOVERY - FACTORS AFFECTING HOSPITAL DISCHARGE IN 152 CONSECUTIVE PATIENTS, THE RELEVANCE OF CD34 DOSE AND THE POTENTIAL IMPLICATIONS OF MEGAKARYOCYTEGROWTH-FACTOR, Blood, 90(10), 1997, pp. 1701-1701
PREEMPTIVE ANTI-CMV THERAPY DURING ALLOGENEIC BONE-MARROW TRANSPLANTATION BASED UPON BLOOD PCR SURVEILLANCE PRODUCES MOLECULAR EVIDENCE OF EFFECTIVE VIRAL CLEARANCE WITH ABSENCE OF CLINICALLY DETECTABLE DISEASE
Authors: PENIKET AJ HOWARD MR PREISER W PERRY AR KOTTARIDIS PD MCKEAG N BRINK NS MACKINNON S GOLDSTONE AH
Citation: Aj. Peniket et al., PREEMPTIVE ANTI-CMV THERAPY DURING ALLOGENEIC BONE-MARROW TRANSPLANTATION BASED UPON BLOOD PCR SURVEILLANCE PRODUCES MOLECULAR EVIDENCE OF EFFECTIVE VIRAL CLEARANCE WITH ABSENCE OF CLINICALLY DETECTABLE DISEASE, Blood, 90(10), 1997, pp. 2423-2423
CHRONIC RELAPSING HODGKINS-DISEASE - AN ANALYSIS OF 167 CASES FROM THE BRITISH NATIONAL LYMPHOMA (BNLI) DATABASE
Authors: PENIKET AJ HUDSON GV ANDERSON L LINCH DC
Citation: Aj. Peniket et al., CHRONIC RELAPSING HODGKINS-DISEASE - AN ANALYSIS OF 167 CASES FROM THE BRITISH NATIONAL LYMPHOMA (BNLI) DATABASE, Blood, 88(10), 1996, pp. 892-892
A COMPARISON OF ESHAP-CSF VS CYCLOPHOSPHAMIDE 1.5G(G)M(2)+G-CSF FOR PBSC MOBILIZATION IN PRETREATED LYMPHOMA PATIENTS - A MATCHED-PAIR ANALYSIS/
Authors: WATTS MJ LEVERETT D SULLIVAN AM PENIKET AJ PERRY AR MACMILLAN A GOLDSTONE AH LINCH DC
Citation: Mj. Watts et al., A COMPARISON OF ESHAP-CSF VS CYCLOPHOSPHAMIDE 1.5G(G)M(2)+G-CSF FOR PBSC MOBILIZATION IN PRETREATED LYMPHOMA PATIENTS - A MATCHED-PAIR ANALYSIS/, Blood, 88(10), 1996, pp. 1571-1571
Risultati: 1-14 |